hit counter
Applied Genetic Technologies Corporation (AGTC) Stock News Sentiment & Price - Sentifly
AGTC - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Applied Genetic Technologies Corporation (AGTC)

USA
Biotechnology
NASDAQ
AGTC Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AGTC Latest news
Seeking Alpha
Neutral
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q1 Fiscal Year 2022 Results - Earnings Call Transcript
2021-11-09 12:54

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q1 Fiscal Year 2022 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
2021-11-09 09:56

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021
2021-11-09 07:00

-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022-

GlobeNewsWire
Neutral
AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021
2021-11-02 08:00

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced that it will report financial results for the quarter ended September 30, 2021 before the market opens on Tuesday, November 9, 2021. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update.

GlobeNewsWire
Neutral
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
2021-10-19 08:00

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021.

GlobeNewsWire
Neutral
AGTC Announces Two Key Leadership Team Appointments
2021-10-14 17:00

- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations -

GlobeNewsWire
Neutral
AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
2021-10-12 11:08

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the 2021 Cell & Gene Meeting on the Mesa being held October 12-14, 2021.

GlobeNewsWire
Neutral
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
2021-09-27 08:00

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thursday, September 30th, 2021.

Benzinga
Negative
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
2021-09-24 09:59

After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation (NASDAQ: AGTC) has run into safety problems.  The Company recently enrolled six pediatric achromatopsia (ACHM) with CNGB3 gene mutation and five pediatric ACHM patients with CNGA3 mutation in high dose groups 5a and 6a.

Seeking Alpha
Neutral
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
2021-09-23 22:38

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript

Loading more news...